HGSI shareholder sues, says board’s poison pill holds shareholders hostage
Not all Human Genome Science (NASDAQ:HGSI) shareholders agree with the company position that GlaxoSmithKline‘s (NYSE:GSK) $2.6 billion purchase offer is insufficient. An HGS shareholder has filed a suit against the board and asked a court to temporarily restrain the Maryland company from using a “poison pill” to fend off the hostile takeover attempt. In the […]